Christopher A. Lipinski

Christopher A. Lipinski's AcademicInfluence.com Rankings

Chemistry

#523

World Rank

#939

Historical Rank

Organic Chemistry

#67

World Rank

#97

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Christopher A. Lipinski's Degrees

Bachelors Chemistry University of Connecticut

Why Is Christopher A. Lipinski Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Christopher A. Lipinski is a medicinal chemist who is working at Pfizer, Inc. He is known for his "rule of five", an algorithm that predicts drug compounds that are likely to have oral activity. By the number of citations, he is the most cited author of some pharmacology journals: Journal of Pharmacological and Toxicological Methods, Advanced Drug Delivery Reviews, Drug Discovery Today: Technologies.

(See a Problem?)

Christopher A. Lipinski's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. (2001) (10289)
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings (1997) (6202)
Lead- and drug-like compounds: the rule-of-five revolution. (2004) (3287)
Drug-like properties and the causes of poor solubility and poor permeability. (2000) (2844)
Navigating chemical space for biology and medicine (2004) (857)
Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. (2016) (292)
Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. (2006) (184)
The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. (2005) (134)
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. (1997) (132)
Chris Lipinski discusses life and chemistry after the Rule of Five. (2003) (122)
A crowdsourcing evaluation of the NIH chemical probes. (2009) (111)
Targeting Pyk2 for therapeutic intervention (2010) (100)
Chapter 27. Bioisosterism in Drug Design (1986) (83)
Badapple: promiscuity patterns from noisy evidence (2016) (81)
Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation. (2003) (72)
Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis. (2010) (71)
Target validation: Determining druggability (2007) (67)
High throughput sonication: evaluation for compound solubilization. (2005) (62)
2006 drug approvals: finding the niche (2007) (60)
Geldanamycin Provides Posttreatment Protection Against Glutamate‐Induced Oxidative Toxicity in a Mouse Hippocampal Cell Line (1999) (57)
Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824. (2008) (57)
Chris Lipinski discusses life and chemistry after the Rule of Five. (2003) (52)
Safety of epinephrine for anaphylaxis in the emergency setting. (2013) (47)
Small molecules with antiviral activity against the Ebola virus (2015) (43)
Medicinal chemistry of aldose reductase inhibitors (1988) (37)
Emergency department rapid medical assessment: overall effect and mechanistic considerations. (2015) (35)
The rule of five should not impede anti-parasitic drug development (2017) (34)
Team strategies and tools to enhance performance and patient safety training: The effect of training on both nursing staff perceptions regarding physician behaviors and patient satisfaction scores in the ED (2015) (34)
Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors. (1992) (32)
The Lyn Kinase Activator MLR-1023 Is a Novel Insulin Receptor Potentiator that Elicits a Rapid-Onset and Durable Improvement in Glucose Homeostasis in Animal Models of Type 2 Diabetes (2012) (31)
Chapter 17. Aldose Reductase Inhibitors as a New Approach to the Treatment of Diabetic Complications (1984) (30)
Capter 11 Filtering in Drug Discovery (2005) (30)
Bioisosteric design of conformationally restricted pyridyltriazole histamine H2-receptor antagonists. (1983) (30)
Critical role of the FERM domain in Pyk2 stimulated glioma cell migration. (2006) (30)
MLR-1023 Is a Potent and Selective Allosteric Activator of Lyn Kinase In Vitro That Improves Glucose Tolerance In Vivo (2012) (29)
The Pyk2 FERM domain as a target to inhibit glioma migration (2009) (28)
Emergency Department Rotational Patient Assignment. (2016) (28)
Bioisosteric prototype design of biaryl imidazolyl and triazolyl competitive histamine H2-receptor antagonists. (1986) (27)
Free online resources enabling crowd-sourced drug discovery (2009) (27)
pKa, Log P and MedChem CLOGP Fragment Values of Acidic Heterocyclic Potential Bioisosteres (1991) (25)
Parallel Worlds of Public and Commercial Bioactive Chemistry Data (2014) (24)
Extended survival of Pyk2 or FAK deficient orthotopic glioma xenografts (2007) (23)
Aqueous Solubility in Discovery, Chemistry, and Assay Changes (2004) (23)
Computational Prediction and Validation of an Expert's Evaluation of Chemical Probes (2014) (22)
Bronchodilator and antiulcer phenoxypyrimidinones. (1980) (22)
Total synthesis of terpenes. XIX. Synthesis of 8-methoxy-4a.beta., 10b.beta., 12a.alpha.-trimethyl-3,4,4a,4b.alpha.,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one, a key intermediate in the total synthesis of (+-)-shionone (1975) (21)
Physical parameters for brian uptake: optimizing log P, log D and pKa of T H A (1991) (21)
Pseudosymmetry and bioisosterism in biaryl pyridyl competitive histamine H2-receptor antagonists. (1985) (20)
Compound Properties and Drug Quality (2008) (20)
Transmission of substituent effects in heterocycles. Rates of solvolysis of substituted 1-(2-thienyl)ethyl p-nitrobenzoates (1972) (19)
Funding for accelerating drug development initiative critical (2006) (18)
Sex expression in gymnosperms (1990) (17)
Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods (2015) (16)
Structural conservation in band 4.1, ezrin, radixin, moesin (FERM) domains as a guide to identify inhibitors of the proline-rich tyrosine kinase 2. (2010) (15)
Total synthesis of dl-shionone, a tetracyclic triterpene (1974) (15)
Physician in Triage Versus Rotational Patient Assignment. (2016) (15)
An improved preparation and use of 2-bromoacetoacetaldehyde in a new synthesis of 2-substituted-4-acetylimidazoles (1984) (13)
Drug Solubility in Water and Dimethylsulfoxide (2007) (12)
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development q settings (1996) (12)
Emergency department physician telemedical triage. (2013) (11)
Correlation of the reactivity of thiophene derivatives (1970) (11)
Securing the future of the clinician-scientist (2020) (11)
Solubility in the Design of Combinatorial Libraries (2004) (11)
The anti-intellectual effects of intellectual property. (2006) (11)
Olfactory and gustatory hallucinations presenting as partial status epilepticus because of glioblastoma multiforme. (2010) (10)
Phenotypic In Vivo Screening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates (2012) (9)
Big pharma slims down to bolster productivity (2007) (9)
The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis (2010) (9)
A unified approach to systematic isosteric substitution for acidic groups and application to NMDA antagonists related to 2-amino-7-phosphonoheptanoate. (1990) (9)
N‐chlorination of dilantin and sorbinil (1990) (8)
High throughput in vivo phenotypic screening for drug repurposing: Discovery of MLR-1023 a novel insulin sensitizer and novel Lyn kinase activator with clinical proof of concept. (2020) (8)
Overview of Hit to Lead: The Medicinal Chemist's Role from HTS Retest to Lead Optimization Hand Off (2009) (8)
Chemical Tools for Indications Discovery (2005) (8)
Chris Lipinski (2012) (8)
A perspective of aldose reductase inhibitors (1993) (8)
Screening: Dirty drugs' secrets uncovered (2006) (7)
Serum Lactate and Mortality in Emergency Department Patients with Cancer (1996) (7)
The utility of the coupling reaction between propargyl grignard reagent and allylic halides for the synthesis of acetylenes (1970) (7)
Single-mode compound retrieval for QSAR, QSPR data sets, and batch mode exact structure searching. (2002) (6)
Drug metabolism: Small but significant (2004) (6)
Targets and mechanisms. (2001) (5)
Acidic isostere design: Synthetic strategies and recent progress in understanding electronic properties and metabolic stability (1990) (5)
Nuclear receptors: Choosing the right path (2005) (5)
Something old and something new: taking cancer therapy forward. (2001) (4)
Flashback phenomenon and residual neurological deficits after the use of "bath salt" 3, 4- methylenedioxypyrovalerone. (2014) (4)
2‐Amino‐ and 2‐guanidino‐4‐thiazolylpyrimidines (1985) (4)
Peter Goodfellow on how automation can aid innovation in the pharma industry (2003) (4)
Gene expression: Do microarrays match up? (2005) (4)
Chapter 6:Phenotypic and In Vivo Screening: Lead Discovery and Drug Repurposing (2012) (3)
Biotechnology : Pharmaceutical Aspects (2008) (3)
Acute rupture of an arachnoid cyst after a minor head injury. (1997) (3)
Gene expression: Do microarrays match up? (2005) (3)
Neurons go to great lengths for new therapy. (2001) (2)
Stealthy polymers target drug-resistant tumour cells. (2001) (2)
Topological proteomics: a new approach to drug discovery. (2001) (2)
Chapter Two - My Perspective on Time, Managers—and Scientific Fun (2013) (2)
G-Protein-coupled receptors: Bridging the GPCR gap (2006) (2)
The Internet in clinical trials: breaking the bottleneck? (2001) (2)
Simon Campbell CBE, FMedSci, FRS (2006) (2)
Can making a correlation be patented? (2005) (2)
Drug Delivery Systems: Entering the Mainstream (2004) (2)
Diaphragmatic rupture: suspicion holds the key to prehospital diagnosis. (1997) (2)
John Weinstein discusses information-intensive approaches to cancer drug discovery. (2001) (2)
Flashback phenomenon and residual neurological deficits after the use of “bath salt” 3, 4- methylenedioxypyrovalerone (2014) (2)
Chemical biology: Modulating molecular gateways (2006) (1)
Drug metabolism: Enigmatic enzyme (2006) (1)
Nuclear receptors: Growing concern for tamoxifen (2004) (1)
BRONCHODILATOR AND ANTIULCER PHENOXYPYRIMIDINONES (1981) (1)
New option for reversible suppression of menstruation. (2001) (1)
Chapter 10. Preclinical. A Repurposed Novel Lyn Kinase Activator, MLR-1023, is a Model Example of Pharmacological Pleiotropy (2022) (1)
Drug resistance: Passing on protection (2005) (1)
Structural biology: Not so crystal clear (2004) (1)
G-Protein-coupled receptors: It takes two... (2005) (1)
Sweet success for Pfizer (2006) (1)
Ian Humphery-Smith on current challenges in proteomics (2003) (1)
Self-regulating insulin bioreactors for diabetes. (2002) (1)
Screening: Screen if you want to go faster! (2004) (1)
Supreme court set to rule on obviousness (2007) (1)
Nursing the drug addict. (1968) (1)
Physical Education Activity for Everyone. (1981) (0)
Erratum: A crowdsourcing evaluation of the NIH chemical probes (2009) (0)
Role Of Pyk2 In Delaying Apoptosis Of Human Neutrophils (2010) (0)
Method C-4-hydroxy-2-r- (substituted) preparation of the novel therapeutically useful chroman-4-acetic acid derivatives (1987) (0)
Developing a new model of care for patients with cancer who present to the emergency department: The Mayo Clinic experience. (2014) (0)
AAPS Update (2005) (0)
That the monitor foerfarande Foer framstaellning of 2-guanidino-4- (2-substituted-amino-4-imidazolyl) tiazoler Science ratio foerfarandes nya mellanprodukter. (1983) (0)
Imidazolylpyridiner therapeutic efficacy. (1986) (0)
pyrimidinones and new hydroxypyrimidines News (1973) (0)
Recruitment and localization of eosinophils to glioma (2007) (0)
EXPERIMENTS DIRECTED TOWARD THE TOTAL SYNTHESIS OF TERPENES PART 19, SYNTHESIS OF 8-METHOXY-4A BETA,10B BETA,12A ALPHA-TRIMETHYL-3,4,4A,4B ALPHA,5,6,10B,11,12A-DECAHYDROCHRYSEN-1(2H)-ONE, A KEY INTERMEDIATE IN THE TOTAL SYNTHESIS OF ( (1975) (0)
Rules and filters and their impact on success in chemical biology and drug discovery (2014) (0)
PYRIMIDINE COMPOUNDS AS PROTEIN KNASE INHIBITORS (2017) (0)
Extended Abstract: The Less Conventional Side of Carbonates (2014) (0)
Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods (2015) (0)
Administration of Emergency Medicine PHYSICIAN IN TRIAGE VERSUS ROTATIONAL PATIENT ASSIGNMENT (0)
AAPS Update (2005) (0)
Chapter 12. Why an In Vivo Screening Platform Covering Broad Therapeutic Spectrum is an Ideal Tool for Drug Repositioning: Illustrated by Discovery of a Novel Class of Insulin Sensitizers (2020) (0)
Characterization of the eIF2-associated protein p67 during brain ischemia and reperfusion (2006) (0)
Improved kinetics and potency of dxl-625 (cd20) compared to rituximab (2008) (0)
Vertebrobasilar distribution stroke mimicking transtentorial herniation. (1998) (0)
Chemist's Role from HTS Retest to Lead (2009) (0)
MOLECULAR DOCKING STUDIES AND DETERMINATION OF DRUG LIKENESS AND ADMET PROPERTIES OF CHALCONES AND CURCUMIN-QUINOLONE HYBRIDS 5 . 1 (2017) (0)
Phenotypic screening of low molecular weight compounds is rich ground for repurposed, on-target drugs (2022) (0)
Interplay of Protein Sequence and Structure: A Concept with Broad Implications in Biology and Molecular Design (2008) (0)
LIGHTS AND EMPYEMA CRITERIA FOR THE DIAGNOSIS OF PURULENT PERICARDITIS (2020) (0)
Pyk2 Signaling Events Mediate Eosinophil Chemotaxis Along Chemoattractant Gradients In The Lung (2007) (0)
Chapter 10. Agents Affecting Gastrointestinal Functions (1975) (0)
A Perspective on the Evolution of Collaborative Drug Discovery and Future Challenges (2014) (0)
2-Amino- and 2-Guanidino-4-thiazolylpyrimidines. (1986) (0)
Beautiful Biology But Bad Chemistry: Recognizing Chemistry Problems Earlier Rather Than Later (2009) (0)
BIOISOSTERIC DESIGN OF CONFORMATIONALLY RESTRICTED PYRIDYLTRIAZOLE HISTAMINE H2‐RECEPTOR ANTAGONISTS (1983) (0)
Process for the preparation of 2-guanidino-4-heteroaryl-thiazole compounds or acid addition salts thereof (1981) (0)
Analogifremgangsmaade for the preparation of 5 '- (2-amino-4-pyridyl) -1', 2 ', 4'-triazol-compounds or pharmaceutically acceptable acid addition salts thereof as well as 5' - (2-halo-4-pyridyl) -1 ' , 2 ', 4', - triazole compounds for use in the method (1982) (0)
Chris Lipinski (2005) (0)
'Optional' ingredients anticipate (2005) (0)
Arthur Holden: banking on our genes (2003) (0)
Antifungal drugs: A helping hand (2005) (0)
RNA interference: Knocked down for the count (2005) (0)
Merck and Integra battle on (2005) (0)
T.P.39 Building muscle with myostatin inhibitors (2012) (0)
Antibacterial drugs: Peptide power (2005) (0)
David Brown: proteomics in drug discovery (2003) (0)
G-Protein-coupled receptors: Better beta-blockers (2005) (0)
Antibacterial drugs: Riboswitching off bacterial growth (2007) (0)
Neurological disorders: Food for thought (2006) (0)
Darren Carroll (2007) (0)
The enemy within: Hormones and cancer (2006) (0)
High-throughput screening: Parallel lines (2006) (0)
Evolution: A helping hand (2005) (0)
Screening: Single cell screens (2005) (0)
Protein–protein interactions: Muscling in on p53 (2006) (0)
Computational chemistry: Flexible approach to drug design (2004) (0)
Biomarkers: Signatures of schizophrenia (2006) (0)
Generics pay-offs prohibited. (2006) (0)
Informatics: Finding common ground (2007) (0)
Holy Grail of drug delivery caught using novel fishnet technology. (2001) (0)
2006 drug approvals: finding the niche (2007) (0)
Kinases: Making gains on glioma (2004) (0)
Food for thought (2006) (0)
Antimicrobial drugs: Accept some substitutes (2005) (0)
Pat Price discusses the potential of molecular imaging for drug development (2003) (0)
EC fines AstraZeneca in Losec antitrust case (2005) (0)
Lipitor scope upheld but second patent invalid (2005) (0)
Interleukin proteins provoke antiviral response in asthma (2001) (0)
Genentech calm Cabilly storm (2005) (0)
Cancer: Know thy enemy (2006) (0)
A new title for TARGETS in 2004 (2004) (0)
Cardiovascular disease: Plumbing for the heart (2004) (0)
Proteases: Joint advantage (2005) (0)
More court rulings safeguard Lipitor (2006) (0)
New genes linked to schizophrenia. (2001) (0)
Courts clash on written description (2005) (0)
Friends in high places. (2006) (0)
Structure-Based Drug Design: Seeking selectivity (2005) (0)
Paxil: part of the process. (2006) (0)
A New Year for TARGETS, and a new Editor (2003) (0)
Screening: Finding cancer's Achilles' heel (2006) (0)
Abbott loses anaesthetic drug patent (2006) (0)
Missed opportunities in pharma? (2004) (0)
Getting on the right career ladder (2005) (0)
Antifungals: A helping hand (2005) (0)
Pharma allowed to make own generics (2005) (0)
HIV: Rat to the rescue (2007) (0)
Anticancer drugs: Double strike (2005) (0)
Milking nature for Alzheimer's treatment. (2001) (0)
Chemistry: Chemical engineering in vivo (2004) (0)
Paul Herrling (2007) (0)
Infectious diseases: Double trouble (2005) (0)
No winners in Rasmusson versus SKB case (2005) (0)
Flower power: fact or fiction? (2001) (0)
Antimicrobial drugs: Riboswitching off bacterial growth (2007) (0)
Personalized medicine: Predicting predisposition (2006) (0)
Chemical biology: Building blocks for peptide drugs (2004) (0)
Lead discovery: Cell death by design (2005) (0)
A sticky end for pathogens? (2001) (0)
Flexible working attracts women to industry (2004) (0)
Chemistry: Stabilizing staples (2004) (0)

This paper list is powered by the following services:

Other Resources About Christopher A. Lipinski

en.wikipedia.org

What Schools Are Affiliated With Christopher A. Lipinski?

Christopher A. Lipinski is affiliated with the following schools:

Christopher A. Lipinski's Academic­Influence.com Rankings